CANADA; Dangers of the H1N1 Vaccine Revealed: More than 100,000 Doses Withdrawn


Region: News Staff

Date: Thu. Nov. 19 2009 11:07 PM ET

More than 100,000 doses of the H1N1 vaccine were withdrawn Thursday, due to a warning that one particular batch of the vaccine had a higher than usual amount of adverse reactions among patients.

Vaccine manufacturer Glaxo Smith Kline has asked several provinces to set aside 170,000 doses of a particular batch. One or two allergic reactions were expected in patients getting the 170,000 doses, but health officials recorded six adverse reactions.

“We’ve been asked by the manufacturer Glaxo Smith Kline not to use this vaccine at this time, pending further investigation,” said Dr. Joel Kettner, Manitoba’s Chief Medical Officer of Health, at a press conference Thursday.

There have been a few sporadic reports of reactions around the country, but officials have stressed that the benefits of the shot far outweighs the risks.

Still, experts say the allergic reaction is worrying.

“It is a serious thing that has the potential to kill — but fortunately seems to be relatively rare,” said Dr. Neil Rau, an infectious disease expert, in an interview with CTV’s John Vennavally-Rao.

Outside of Manitoba, about 1,500 doses of the vaccine were sent to Ontario, but officials say that none have so far been administered.

VIDEO: Batch of H1N1 vaccine causes adverse reactions
To View CTV Video Report Click Here

Comment on Global Research Articles on our Facebook page

Become a Member of Global Research

Articles by: Global Research

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: [email protected] contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: [email protected]